Astellas Enters a ~$1.54B Licensing Agreement with Evopoint Biosciences to Develop & Commercialize XNW27011

Shots:

• Evopoint Biosciences has granted Astellas exclusive license to develop & commercialize XNW27011 globally, excl. Mainland China, Hong Kong, Macao & Taiwan
• As per the deal, Evopoint will receive $130M upfront as well as ~$70M as near-term payments in addition to ~$1.34B in development, regulatory & commercial milestones, with net sales-based royalties
• XNW27011, an CLDN18.2-specific ADC with TOP1 inhibitor payload & linker tech, is being evaluated in P-I/II trials in China for CLDN18.2-positive solid tumors incl. gastric, gastroesophageal, & pancreatic cancers

Ref:  Astellas| Image:  Astellas & Evopoint Bio| Press Release

Related News:- Astellas Collaborates with Chromatin Bioscience to Develop Cell-Selective Synthetic Promoters

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com